AbCellera raises $200M after Phase 2 win; Silence Therapeutics raises $175M post-Phase 2 success in rare blood cancer; InduPro closes $77M Series B.
August 12, 2026 11:25 AM EDT
News Briefing
AbCellera, Silence and InduPro all raise significant funding
AbCellera’s $200M offering: The Vancouver biotech is selling shares after hitting the bar in a Phase 2 hot …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
What's Going on With AbCellera Biologics Stock On Wednesday? - AbCellera Biologics (NASDAQ:ABCL)
Silence Therapeutics aims at Takeda with new data in rare blood cancer
